US OptionsDetailed Quotes

NVCR240517P15000

Watchlist

0.03
0.000.00%

15min DelayClose May 17 15:10 ET

0.00High0.00Low

Novocure Stock Discussion

Kenneil Nugent

Mar 27 22:17

$Novocure(NVCR.US)$ pt anyone?

74338962

Mar 27 21:51

$Novocure(NVCR.US)$ I placed limit buy @13.1 but got filled at 13.299, I noticed this many times in this app, they are causing slippage, anyone noticed same?

zine1

Mar 27 20:52

$iBio Inc (IBIO.US)$ IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.
DRCT: -49% | Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.
NVCR: 42% | Novocure shares are trading higher after the company's METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial ...

Movers and Shakers

Mar 27 20:28

ColumnsToday's Morning Movers and Top Ratings: MRNA, GME, MRK, CCL and More

Morning Movers
Gapping up
$Deutsche Bank(DB.US)$ shares rose 3% after Morgan Stanley upgraded the stock to overweight, suggesting further potential growth following a strong performance in 2024.
$Merck & Co(MRK.US)$ stock rose 4.8% after its drug for treating a rare lung disease received FDA approval.
$Trump Media & Technology(DJT.US)$ stock jumped 14%, following gains after its Nasdaq debut.
$Robinhood(HOOD.US)$ stock climbed 6...

mooster Han

Mar 27 20:06

Merck Soars, GameStop Plummets in Pre-Market Drama

Key Takeaway
GameStop ( $GameStop(GME.US)$ ) and Forge Global ( $Forge Global(FRGE.US)$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure(NVCR.US)$ ) surges 30% on positive trial results.
Merck ( $Merck & Co(MRK.US)$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...

Moomoo AI

Mar 4 21:09

The 23% annualized share price decline underscores the risk of investing in unprofitable firms. The company's poor performance last year may suggest ongoing issues, as it was worse than the 11% annualized loss over the past five years. Prolonged share price weakness can be a negative indicator, though contrarian investors might want to investigate the stock for a potential turnaround.

NovoCure (NASDAQ:NVCR) Adds US$145m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 87%

Meltyy

Mar 4 17:54

🎯 Ph 3 readouts in Q1 2024...

$Pfizer(PFE.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$ Phase 3
$Aquestive Therapeutics(AQST.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$Johnson & Johnson(JNJ.US)$ Phase 3

Meltyy

Feb 22 12:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$ $Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...

Meltyy

Feb 1 04:38

Ph 3 readouts in Q1 2024...

$Pfizer(PFE.US)$ Phase 3
$Regenxbio(RGNX.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Vertex Pharmaceuticals(VRTX.US)$ Phase 3
$KalVista Pharmaceuticals(KALV.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$Applied Therapeutics(APLT.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3...

Mcsnacks H Tupack

Jan 29 13:34

Long hold

$Novocure(NVCR.US)$ FDA accepted their lung therapy application. Buying in at 14.00. Selling at 70.00. About a 5-6 month investment for over 300% profit.

No comment yet